• Daniel C Burger, Ian C Lawrance, Peter A Bampton, Ruth Prosser, Anthony Croft, Kristen Gilshenan, Graham L Radford-Smith, and Timothy H Florin.
• Department of Gastroenterology, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia.
• Med. J. Aust. 2010 Apr 5; 192 (7): 375-7.

ObjectiveTo examine the prevalence of perianal Crohn's disease (PCD) and the eligibility of PCD patients to access anti-tumour necrosis factor-alpha (anti-TNFalpha) treatment under current Australian Pharmaceutical Benefits Scheme (PBS) guidelines.Design, Setting And ParticipantsA retrospective study of patients with Crohn's disease (CD) and PCD attending four large adult inflammatory bowel disease (IBD) centres in Australia between January 2004 and May 2008. Patients for whom anti-TNFalpha therapy was clinically indicated were assessed to determine whether they satisfied PBS criteria for subsidised medication.Main Outcome MeasuresPrevalence of CD and PCD in patients attending different IBD centres; eligibility of PCD patients for PBS-subsidised anti-TNFalpha medication.ResultsData were available on 3589 patients, representing about 6% of all patients with IBD in Australia. Of the 1815 patients with CD, 310 (17%) had PCD. Anti-TNFalpha therapy was deemed clinically indicated for 166 patients with PCD (54%), of whom 49 (30%) did not qualify for PBS-funded therapy.ConclusionThirty per cent of patients with clinically significant PCD currently do not have access to PBS-subsidised optimal medical treatment. We believe that PBS criteria should be extended to include this subgroup of IBD patients.

11 keywords...

hide…